Pilar Garcia-Alfonso
Overview
Explore the profile of Pilar Garcia-Alfonso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
2146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Alfonso P, Valladares-Ayerbes M, Munoz Martin A, Morales Herrero R, Galvez Munoz E, Prat-Llorens G
Expert Opin Biol Ther
. 2025 Mar;
:1-11.
PMID: 40066702
Introduction: Adding monoclonal antibodies to chemotherapy drastically changed the landscape of advanced colorectal cancer. The prediction of benefit from anti-EGFR therapies is mainly based on the absence of mutations in...
2.
Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, et al.
Eur J Cancer
. 2025 Feb;
218:115268.
PMID: 39952149
Introduction: Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539). Methods: Patients were...
3.
Munoz C, Riesco Martinez M, Ugidos L, Garcia-Alfonso P, Alvarez-Gallego R, Peinado P, et al.
Am J Clin Oncol
. 2024 Nov;
48(3):142-147.
PMID: 39610155
Objective: To evaluate the efficacy of neoadjuvant chemotherapy combination with liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin in patients with locally advanced rectal cancer. Methods: This was a phase 2, nonrandomized,...
4.
Lenz H, Liu T, Chen E, Horvath Z, Bondarenko I, Danielewicz I, et al.
JNCI Cancer Spectr
. 2024 Nov;
9(1).
PMID: 39579142
Background: In metastatic colorectal cancer (mCRC), improvements in survival from combining leucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) with bevacizumab have come at the risk of increased rates of high-grade toxicities. Trilaciclib is indicated to...
5.
Garcia-Alfonso P, Jimenez-Fonseca P, Soto-Alsar J, Baraibar I, Santos C, La Casta A, et al.
Oncologist
. 2024 Nov;
PMID: 39550209
Introduction: The initial SARS-CoV-2 pandemic wave in Spain in 2020 precipitated significant paradigm shifts in gastrointestinal oncology patient management. This study captures the "Zeitgeist" of this period by analyzing adaptive...
6.
Kawazoe A, Xu R, Garcia-Alfonso P, Passhak M, Teng H, Shergill A, et al.
J Clin Oncol
. 2024 Jun;
42(24):2918-2927.
PMID: 38833658
Purpose: Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with...
7.
Overman M, Gelsomino F, Aglietta M, Wong M, Limon Miron M, Leonard G, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38821718
Background: Programmed death-1 (PD-1) inhibitors, including nivolumab, have demonstrated long-term survival benefit in previously treated patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (CRC). PD-1 and lymphocyte-activation gene 3...
8.
Takashima A, Garcia-Alfonso P, Manneh R, Besen A, Hong Y, Cuyle P, et al.
Eur J Cancer
. 2024 May;
205:114036.
PMID: 38749110
Background: The randomized, open-label, phase III LYNK-003 study assessed the efficacy of first-line maintenance olaparib, alone or in combination with bevacizumab, versus bevacizumab plus a fluoropyrimidine in participants with unresectable...
9.
Valladares-Ayerbes M, Safont M, Gonzalez Flores E, Garcia-Alfonso P, Aranda E, Munoz A, et al.
Clin Transl Oncol
. 2024 Apr;
26(10):2640-2651.
PMID: 38642257
Purpose: RAS (KRAS/NRAS) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS mutational status by tumor-tissue biopsy is...
10.
Rodriguez-Lescure A, Gallego J, Garcia-Alfonso P, Massuti B, Marquez R, Calvo L, et al.
Clin Transl Oncol
. 2024 Apr;
26(8):1896-1907.
PMID: 38578537
Background: Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT. Methods: This prospective observational study conducted...